Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the Groupe d'Etudes et de Recherche sur …
…, P Delaval, J Cadranel, P Bonniaud, G Prévot… - Autoimmunity …, 2017 - Elsevier
Objective To guide nosology and classification of patients with eosinophilic granulomatosis
with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods …
with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods …
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
Current European guidelines recommend periodic risk assessment for patients with
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
V Cottin, J Le Pavec, G Prévot, H Mal… - European respiratory …, 2010 - Eur Respiratory Soc
This study aims to describe the haemodynamic and survival characteristics of patients with
pulmonary hypertension in the recently individualised syndrome of combined pulmonary …
pulmonary hypertension in the recently individualised syndrome of combined pulmonary …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
…, MT Leccia, M Jaffro, S Collot, G Prévot… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open …
…, P Magro, L Savale, G Prévot… - The Lancet …, 2022 - thelancet.com
Background Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for
inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised …
inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised …
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double …
…, N Zhang, Y Mi, X Zhu, P Jansa, G Prévot… - The Lancet …, 2017 - thelancet.com
Background Macitentan is beneficial for long-term treatment of pulmonary arterial
hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) …
hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) …
[HTML][HTML] External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
…, P De Groote, V Cottin, G Prévot… - European …, 2022 - Eur Respiratory Soc
Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial
hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk …
hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk …
Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension
…, F Picard, J Pichon, P Poubeau, G Prévot… - American journal of …, 2021 - atsjournals.org
Rationale: The relationship between the initial treatment strategy and survival in pulmonary
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival …
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival …
Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis
…, J Cadranel, B Wallaert, A Tazi, B Maître, G Prévot… - Thorax, 2018 - thorax.bmj.com
Introduction Idiopathic pulmonary fibrosis (IPF) has an unpredictable course corresponding
to various profiles: stability, physiological disease progression and rapid decline. A minority …
to various profiles: stability, physiological disease progression and rapid decline. A minority …
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis
…, V Cottin, S Marchand-Adam, G Prevot… - European …, 2016 - Eur Respiratory Soc
Telomerase reverse transcriptase (TERT) or telomerase RNA (TERC) gene mutation is a
major monogenic cause of pulmonary fibrosis. Sequencing of TERT/TERC genes is proposed …
major monogenic cause of pulmonary fibrosis. Sequencing of TERT/TERC genes is proposed …